BETRF BetterLife Pharma Inc. IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1464165 · Reporting currency CAD · Fiscal year ends 01/31
Financial factors as of 2025-01-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2025*2025-01-31 | FY2024*2024-01-31 | FY2023*2023-01-31 | FY2022*2022-01-31 | FY2021*2021-01-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | 424,337 | 570,947 | 2.68M | 5.42M | 284,700 |
| SG&A expense | 260,500 | 271,731 | 280,467 | 425,865 | 1.74M |
| Operating income | -5.00M | -3.24M | -9.46M | — | — |
| Interest expense | 165,087 | 45,544 | 11,491 | 51,761 | 7,046 |
| Pretax income | — | -2.90M | -9.37M | -11.99M | -36.35M |
| Net income | -3.52M | -2.89M | -9.02M | -12.16M | -36.35M |
| EBITDA | -5.00M | -3.24M | -9.44M | — | — |
| EPS (basic) | — | — | — | — | -1.34 |
| EPS (diluted) | -0.03 | -0.03 | -0.10 | -0.16 | -1.34 |
| Weighted avg. shares (diluted) | — | — | — | 438,095 | 0 |
| Balance sheet | |||||
| Cash & equivalents | 8,180 | 37,384 | 8,307 | 173,513 | 154,722 |
| Receivables | 11,644 | 39,536 | 17,196 | 324,993 | 520,122 |
| Current assets | — | — | 74,727 | 1.14M | 1.33M |
| Intangibles | — | — | — | — | 0 |
| Total assets | 224,963 | 324,746 | 74,727 | 1.16M | 1.34M |
| Current liabilities | 7.54M | 7.35M | 7.15M | 4.14M | 5.85M |
| Short-term debt | — | 50,052 | 80,000 | 40,000 | 0 |
| Long-term debt | — | 49,115 | 0 | 34,559 | 0 |
| Total debt | — | 99,167 | 80,000 | 74,559 | 0 |
| Total liabilities | 7.59M | 8.02M | 7.61M | 5.04M | 5.98M |
| Shareholders' equity | -10.68M | -10.81M | -10.73M | -3.88M | -4.61M |
| Net debt | — | 61,783 | 71,693 | -98,954 | -154,722 |
| Shares outstanding | 43.49M | 52.81M | 30.14M | 31.26M | — |
| Cash flow statement | |||||
| Operating cash flow | -2.02M | -2.47M | -1.50M | -11.20M | -7.16M |
| Capital expenditure | — | — | — | — | 10,153 |
| Free cash flow | — | — | — | — | -7.18M |
| Investing cash flow | — | — | — | — | -71,550 |
| Financing cash flow | 1.99M | 2.50M | 1.34M | 11.23M | 4.09M |
| Depreciation & amortization | 0 | 0 | 18,435 | 18,436 | — |
| Stock-based compensation | 2.05M | 500,263 | 951,065 | 1.23M | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.